AMRX vs CB · P/E 44, rev $2.79B vs P/E 14, rev $59.40B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the AMRX and CB stock pages for the full models.
Not investment advice.